​

United Therapeutics (UTHR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

UTHR Stock Forecast

United Therapeutics stock forecast is as follows: an average price target of $440.40 (represents a 22.48% upside from UTHR’s last price of $359.58) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

UTHR Price Target

The average price target for United Therapeutics (UTHR) is $440.40 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $575.00 to $370.00. This represents a potential 22.48% upside from UTHR's last price of $359.58.

UTHR Analyst Ratings

Buy

According to 7 Wall Street analysts, United Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for UTHR stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

United Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Jasper HellwegArgus Research$400.00$362.3610.39%11.24%
Oct 31, 2024Andrew FeinH.C. Wainwright$425.00$361.4017.60%18.19%
Sep 23, 2024Eun YangJefferies$432.00$353.0022.38%20.14%
Aug 28, 2024Hartaj SinghOppenheimer$575.00$362.4458.64%59.91%
Jul 08, 2024Ashwani VermaUBS$370.00$317.1816.65%2.90%
Jun 12, 2024Tiago FauthWells Fargo$350.00$275.7626.92%-2.66%
May 02, 2024Hartaj SinghOppenheimer$400.00$255.1456.78%11.24%
Feb 12, 2024Chris ShibutaniGoldman Sachs$215.00$214.740.12%-40.21%
Jan 11, 2023Argus Research$300.00$263.4113.89%-16.57%
Dec 06, 2022Morgan Stanley$330.00$276.0719.53%-8.23%
Dec 06, 2022UBS$320.00$273.7216.91%-11.01%
Dec 05, 2022Goldman Sachs$230.00$278.55-17.43%-36.04%
May 24, 2022J.P. Morgan$238.00$218.009.17%-33.81%
May 24, 2022Jefferies$245.00$217.1312.83%-31.86%
May 24, 2022Credit Suisse$247.00$210.1417.54%-31.31%
May 24, 2022H.C. Wainwright$255.00$210.1421.35%-29.08%
Apr 19, 2022J.P. Morgan$223.00$184.2421.04%-37.98%
May 05, 2021Tiago FauthCredit Suisse$205.00$198.143.46%-42.99%

The latest United Therapeutics stock forecast, released on Oct 31, 2024 by Jasper Hellweg from Argus Research, set a price target of $400.00, which represents a 10.39% increase from the stock price at the time of the forecast ($362.36), and a 11.24% increase from UTHR last price ($359.58).

United Therapeutics Price Target by Period

1M3M12M
# Anlaysts-38
Avg Price Target-$419.00$395.88
Last Closing Price$359.58$359.58$359.58
Upside/Downside-100.00%16.52%10.10%

In the current month, the average price target of United Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to United Therapeutics's last price of $359.58. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2024H.C. WainwrightBuyBuyHold
Oct 21, 2024Wells FargoBuyBuyHold
Oct 21, 2024OppenheimerUnderperformUnderperformHold
Oct 21, 2024Cowen & Co.BuyBuyHold
Sep 23, 2024Wells FargoBuyBuyHold
Sep 23, 2024UBSUnderperformUnderperformHold
Sep 23, 2024JefferiesBuyBuyHold
Aug 28, 2024OppenheimerOutperformOutperformHold
Aug 20, 2024UBSUnderperformUnderperformHold
Aug 20, 2024Wells FargoBuyBuyHold
Aug 20, 2024Wells FargoOverweightOverweightHold
Jul 25, 2024UBSUnderperformUnderperformHold
Jul 25, 2024H.C. WainwrightBuyBuyHold
Jul 11, 2024Cowen & Co.BuyBuyHold
Jul 11, 2024Morgan StanleyOverweightEqual-WeightDowngrade
Jul 08, 2024Wells FargoBuyBuyHold
Jul 08, 2024UBSBuyBuyHold
Jun 27, 2024Bank of America SecuritiesUnderperformUnderperformHold
Jun 12, 2024Wells FargoBuyBuyHold
Jun 12, 2024OppenheimerUnderperformUnderperformHold
Jun 12, 2024Wells FargoOverweightOverweightHold
May 02, 2024Wells FargoBuyBuyHold
May 02, 2024WedbushUnderperformUnderperformHold
May 02, 2024OppenheimerOutperformOutperformHold
Feb 22, 2024WedbushBuyBuyHold
Feb 22, 2024Leerink PartnersUnderperformUnderperformHold
Feb 12, 2024Goldman SachsSellNeutralUpgrade
Dec 06, 2022Morgan StanleyOverweightOverweightHold
Dec 06, 2022UBSBuyInitialise
Dec 05, 2022Goldman SachsSellInitialise
May 24, 2022JefferiesBuyBuyHold
May 24, 2022Cowen & Co.OutperformOutperformHold
May 24, 2022Credit SuissePositivePositiveHold
May 24, 2022Credit SuisseOutperformOutperformHold
Feb 28, 2022WedbushOutperformOutperformHold

United Therapeutics's last stock rating was published by H.C. Wainwright on Oct 31, 2024. The company gave UTHR a "Buy" rating, the same as its previous rate.

United Therapeutics Financial Forecast

United Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue---------$609.40M-$506.90M$491.50M$516.00M$466.90M$461.90M$415.20M$444.70M$446.50M$379.10M$384.60M$380.10M$362.00M$356.30M$311.10M$401.50M$373.60M$362.60M$389.20M$370.50M
Avg Forecast$840.42M$831.46M$800.05M$757.42M$739.92M$722.62M$691.87M$620.31M$575.01M$585.82M$524.18M$514.37M$519.21M$493.21M$461.06M$420.06M$427.59M$421.45M$378.56M$368.95M$362.04M$358.46M$339.98M$344.33M$357.77M$337.60M$332.15M$335.43M$245.96M$315.26M
High Forecast$876.87M$867.52M$834.76M$769.30M$807.97M$724.84M$691.87M$620.31M$610.36M$603.74M$546.91M$536.68M$541.73M$493.21M$461.06M$420.06M$427.59M$421.45M$378.56M$368.95M$362.04M$358.46M$339.98M$344.33M$357.77M$337.60M$332.15M$335.43M$295.15M$378.31M
Low Forecast$805.72M$797.12M$767.02M$745.53M$693.93M$720.39M$691.87M$620.31M$538.02M$561.00M$502.53M$493.13M$497.77M$493.21M$461.06M$420.06M$427.59M$421.45M$378.56M$368.95M$362.04M$358.46M$339.98M$344.33M$357.77M$337.60M$332.15M$335.43M$196.77M$252.21M
# Analysts1113945481099888899999889127781612
Surprise %---------1.04%-0.99%0.95%1.05%1.01%1.10%0.97%1.06%1.18%1.03%1.06%1.06%1.06%1.03%0.87%1.19%1.12%1.08%1.58%1.18%

United Therapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $575.01M, with a low forecast of $538.02M, and a high forecast of $610.36M. UTHR's average Quarter revenue forecast represents a -5.64% decrease compared to the company's last Quarter revenue of $609.40M (Sep 23).

United Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113945481099888899999889127781612
EBITDA---------$327.00M-$319.00M$191.10M$334.60M$169.50M$327.60M$157.80M$221.40M$233.60M$49.60M$-117.50M$235.70M$152.10M$192.20M$90.80M$191.30M$273.00M$-630.00M$319.50M$272.30M
Avg Forecast$328.48M$324.98M$312.70M$296.04M$289.20M$282.44M$270.42M$106.50M$224.74M$228.97M$204.87M$96.82M$237.51M$181.35M$169.53M$88.02M$157.22M$154.96M$139.19M$80.02M$133.12M$131.80M$125.01M$166.34M$131.55M$124.13M$122.13M$-3.44B$146.77M$224.59M
High Forecast$342.73M$339.07M$326.27M$300.68M$315.80M$283.31M$270.42M$127.80M$238.56M$235.97M$213.76M$116.19M$285.01M$181.35M$169.53M$105.62M$157.22M$154.96M$139.19M$96.02M$133.12M$131.80M$125.01M$199.61M$131.55M$124.13M$122.13M$-2.75B$176.12M$269.50M
Low Forecast$314.91M$311.56M$299.79M$291.39M$271.22M$281.57M$270.42M$85.20M$210.28M$219.27M$196.41M$77.46M$190.00M$181.35M$169.53M$70.42M$157.22M$154.96M$139.19M$64.01M$133.12M$131.80M$125.01M$133.07M$131.55M$124.13M$122.13M$-4.13B$117.42M$179.67M
Surprise %---------1.43%-3.29%0.80%1.85%1.00%3.72%1.00%1.43%1.68%0.62%-0.88%1.79%1.22%1.16%0.69%1.54%2.24%0.18%2.18%1.21%

8 analysts predict UTHR's average Quarter EBITDA for Dec 23 to be $224.74M, with a high of $238.56M and a low of $210.28M. This is -31.27% lower than United Therapeutics's previous annual EBITDA (Sep 23) of $327.00M.

United Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113945481099888899999889127781612
Net Income---------$267.60M-$240.90M$132.10M$239.30M$116.00M$239.90M$112.20M$162.70M$172.60M$28.30M$98.00M$171.20M$107.10M$137.70M$52.60M$132.40M$205.10M$-494.60M$244.50M$178.60M
Avg Forecast$377.84M$400.87M$384.30M$351.67M$318.94M$315.73M$314.86M$60.77M$202.66M$246.93M$221.14M$55.24M$168.87M$185.70M$208.49M$50.22M$170.05M$170.64M$143.45M$45.66M$140.18M$134.96M$131.71M$119.17M$125.45M$120.65M$117.74M$-2.70B$112.32M$147.30M
High Forecast$399.15M$423.48M$405.97M$355.78M$391.49M$315.82M$315.36M$72.92M$256.43M$275.61M$233.61M$66.29M$202.65M$185.70M$208.49M$60.27M$170.05M$170.64M$143.45M$54.79M$140.18M$134.96M$131.71M$143.01M$125.45M$120.65M$117.74M$-2.16B$134.78M$176.77M
Low Forecast$357.56M$379.35M$363.67M$347.05M$253.44M$315.64M$314.37M$48.61M$153.55M$194.92M$209.27M$44.19M$135.10M$185.70M$208.49M$40.18M$170.05M$170.64M$143.45M$36.52M$140.18M$134.96M$131.71M$95.34M$125.45M$120.65M$117.74M$-3.24B$89.85M$117.84M
Surprise %---------1.08%-4.36%0.78%1.29%0.56%4.78%0.66%0.95%1.20%0.62%0.70%1.27%0.81%1.16%0.42%1.10%1.74%0.18%2.18%1.21%

United Therapeutics's average Quarter net income forecast for Dec 23 is $202.66M, with a range of $153.55M to $256.43M. UTHR's average Quarter net income forecast represents a -24.27% decrease compared to the company's last Quarter net income of $267.60M (Sep 23).

United Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113945481099888899999889127781612
SG&A---------$127.60M-$87.30M$166.10M$98.40M$141.50M$79.00M$127.90M$109.10M$112.80M$117.20M$103.80M$66.30M$105.90M$93.00M$105.20M$99.40M$39.60M$92.00M$-6.60M$56.40M
Avg Forecast$210.34M$208.10M$200.24M$189.57M$185.19M$180.86M$173.16M$251.66M$143.91M$146.62M$131.19M$228.78M$192.50M$123.44M$115.39M$207.98M$107.02M$105.48M$94.75M$189.07M$90.61M$89.72M$85.09M$80.49M$89.54M$84.50M$83.13M$83.95M$-3.03M$46.52M
High Forecast$219.46M$217.12M$208.92M$192.54M$202.22M$181.41M$173.16M$301.99M$152.76M$151.10M$136.88M$274.54M$231.00M$123.44M$115.39M$249.58M$107.02M$105.48M$94.75M$226.89M$90.61M$89.72M$85.09M$96.58M$89.54M$84.50M$83.13M$83.95M$-2.43M$55.82M
Low Forecast$201.65M$199.50M$191.97M$186.59M$173.68M$180.30M$173.16M$201.33M$134.65M$140.41M$125.77M$183.02M$154.00M$123.44M$115.39M$166.39M$107.02M$105.48M$94.75M$151.26M$90.61M$89.72M$85.09M$64.39M$89.54M$84.50M$83.13M$83.95M$-3.64M$37.21M
Surprise %---------0.87%-0.38%0.86%0.80%1.23%0.38%1.20%1.03%1.19%0.62%1.15%0.74%1.24%1.16%1.17%1.18%0.48%1.10%2.18%1.21%

United Therapeutics's average Quarter SG&A projection for Dec 23 is $143.91M, based on 8 Wall Street analysts, with a range of $134.65M to $152.76M. The forecast indicates a 12.78% rise compared to UTHR last annual SG&A of $127.60M (Sep 23).

United Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts1113945481099888899999889127781612
EPS---------$5.71-$5.20$2.88$5.26$2.56$5.31$2.49$3.62$3.85$0.63$2.22$3.86$2.43$3.14$1.20$3.02$4.68$-11.32$5.65$4.01
Avg Forecast$7.81$8.28$7.94$7.27$6.59$6.52$6.51$5.74$4.19$5.10$4.57$4.59$4.72$3.91$4.39$3.65$3.58$3.59$3.02$3.03$2.95$2.84$2.77$2.74$2.64$2.54$2.48$2.72$1.62$2.73
High Forecast$8.25$8.75$8.39$7.35$8.09$6.53$6.52$5.76$5.30$5.69$4.83$4.85$4.99$3.91$4.39$3.65$3.58$3.59$3.02$3.03$2.95$2.84$2.77$2.74$2.64$2.54$2.48$2.72$1.94$3.28
Low Forecast$7.39$7.84$7.51$7.17$5.24$6.52$6.50$5.72$3.17$4.03$4.32$4.34$4.47$3.91$4.39$3.65$3.58$3.59$3.02$3.03$2.95$2.84$2.77$2.74$2.64$2.54$2.48$2.72$1.29$2.18
Surprise %---------1.12%-1.13%0.61%1.35%0.58%1.46%0.70%1.01%1.27%0.21%0.75%1.36%0.88%1.15%0.45%1.19%1.89%-4.17%3.49%1.47%

According to 8 Wall Street analysts, United Therapeutics's projected average Quarter EPS for Dec 23 is $4.19, with a low estimate of $3.17 and a high estimate of $5.30. This represents a -26.67% decrease compared to UTHR previous annual EPS of $5.71 (Sep 23).

United Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences$2.37$33.861328.69%Buy
LRMRLarimar Therapeutics$4.32$17.00293.52%Buy
LEGNLegend Biotech$34.68$89.60158.36%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
MNKDMannKind$5.93$12.00102.36%Buy
RAREUltragenyx Pharmaceutical$44.95$90.00100.22%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
KNSAKiniksa Pharmaceuticals$20.49$37.5083.02%Buy
PCVXVaxcyte$89.86$148.8065.59%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
REPLReplimune Group$11.72$19.0062.12%Buy
ASNDAscendis Pharma$140.30$211.1450.49%Buy
BGNEBeiGene$179.06$267.3349.30%Buy
NUVLNuvalent$88.10$114.8030.31%Buy
INCYIncyte$69.40$90.1129.84%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
ALNYAlnylam Pharmaceuticals$246.58$310.6025.96%Buy
UTHRUnited Therapeutics$379.69$440.4015.99%Buy

UTHR Forecast FAQ

Is United Therapeutics a good buy?

Yes, according to 7 Wall Street analysts, United Therapeutics (UTHR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 71.43% of UTHR's total ratings.

What is UTHR's price target?

United Therapeutics (UTHR) average price target is $440.4 with a range of $370 to $575, implying a 22.48% from its last price of $359.58. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will United Therapeutics stock go up soon?

According to Wall Street analysts' prediction for UTHR stock, the company can go up by 22.48% (from the last price of $359.58 to the average price target of $440.4), up by 59.91% based on the highest stock price target, and up by 2.90% based on the lowest stock price target.

Can United Therapeutics stock reach $500?

UTHR's highest twelve months analyst stock price target of $575 supports the claim that United Therapeutics can reach $500 in the near future.

What are United Therapeutics's analysts' financial forecasts?

United Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.77B (high $2.84B, low $2.73B), average EBITDA is $948.56M (high $997.32M, low $908.41M), average net income is $1.01B (high $1.1B, low $932.06M), average SG&A $790.86M (high $858.78M, low $728.46M), and average EPS is $25.36 (high $26.89, low $23.98). UTHR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.23B (high $3.35B, low $3.12B), average EBITDA is $1.26B (high $1.31B, low $1.22B), average net income is $1.51B (high $1.58B, low $1.45B), average SG&A $808.24M (high $838.05M, low $779.72M), and average EPS is $31.3 (high $32.73, low $29.91).

Did the UTHR's actual financial results beat the analysts' financial forecasts?

Based on United Therapeutics's last annual report (Dec 2022), the company's revenue was $1.94B, beating the average analysts forecast of $1.89B by 2.26%. Apple's EBITDA was $984.7M, beating the average prediction of $676.4M by 45.58%. The company's net income was $727.3M, beating the average estimation of $613.29M by 18.59%. Apple's SG&A was $487M, missing the average forecast of $639.32M by -23.83%. Lastly, the company's EPS was $15.98, missing the average prediction of $16.67 by -4.13%. In terms of the last quarterly report (Sep 2023), United Therapeutics's revenue was $609.4M, beating the average analysts' forecast of $585.82M by 4.03%. The company's EBITDA was $327M, beating the average prediction of $228.97M by 42.82%. United Therapeutics's net income was $267.6M, beating the average estimation of $246.93M by 8.37%. The company's SG&A was $127.6M, missing the average forecast of $146.62M by -12.97%. Lastly, the company's EPS was $5.71, beating the average prediction of $5.1 by 11.92%